BIOMAT Database Logo BIOMAT Database Logo

Central venous catheter associated thrombosis of major veins: thrombolytic treatment with recombinant tissue plasminogen activator. 1993

S Rodenhuis, and L G van't Hek, and L T Vlasveld, and R Kröger, and R Dubbelman, and R G van Tol
Division of Clinical Oncology, The Netherlands Cancer Institute, Amsterdam.

OBJECTIVE Major thromboses can occur in the venous system in association with central venous catheters. This usually necessitates removal of the catheter. METHODS The effectiveness of low dose recombinant tissue type plasminogen activator (rt-PA) in combination with heparin was assessed in patients with central venous catheter associated thrombosis. RESULTS In five patients, all suffering from cancer, a 5-7 day continuous infusion resulted in complete lysis of the thrombus without complications in three. In the other two patients moderately severe haemorrhage was observed with only partial lysis, of the thrombus. CONCLUSIONS The infusion of heparin and rt-PA is potentially effective in thrombosis related to use of central venous catheters, but the risk of haemorrhage is not inconsiderable.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010865 Pilot Projects Small-scale tests of methods and procedures to be used on a larger scale if the pilot study demonstrates that these methods and procedures can work. Pilot Studies,Pilot Study,Pilot Project,Project, Pilot,Projects, Pilot,Studies, Pilot,Study, Pilot
D010959 Tissue Plasminogen Activator A proteolytic enzyme in the serine protease family found in many tissues which converts PLASMINOGEN to FIBRINOLYSIN. It has fibrin-binding activity and is immunologically different from UROKINASE-TYPE PLASMINOGEN ACTIVATOR. The primary sequence, composed of 527 amino acids, is identical in both the naturally occurring and synthetic proteases. Alteplase,Plasminogen Activator, Tissue-Type,T-Plasminogen Activator,Tissue-Type Plasminogen Activator,Actilyse,Activase,Lysatec rt-PA,TTPA,Tisokinase,Tissue Activator D-44,Lysatec rt PA,Lysatec rtPA,Plasminogen Activator, Tissue,Plasminogen Activator, Tissue Type,T Plasminogen Activator,Tissue Activator D 44,Tissue Type Plasminogen Activator
D002405 Catheterization, Central Venous Placement of an intravenous CATHETER in the subclavian, jugular, or other central vein. Central Venous Catheterization,Venous Catheterization, Central,Catheterization, Central,Central Catheterization,Catheterizations, Central,Catheterizations, Central Venous,Central Catheterizations,Central Venous Catheterizations,Venous Catheterizations, Central
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D005260 Female Females
D006470 Hemorrhage Bleeding or escape of blood from a vessel. Bleeding,Hemorrhages
D006493 Heparin A highly acidic mucopolysaccharide formed of equal parts of sulfated D-glucosamine and D-glucuronic acid with sulfaminic bridges. The molecular weight ranges from six to twenty thousand. Heparin occurs in and is obtained from liver, lung, mast cells, etc., of vertebrates. Its function is unknown, but it is used to prevent blood clotting in vivo and vitro, in the form of many different salts. Heparinic Acid,alpha-Heparin,Heparin Sodium,Liquaemin,Sodium Heparin,Unfractionated Heparin,Heparin, Sodium,Heparin, Unfractionated,alpha Heparin

Related Publications

S Rodenhuis, and L G van't Hek, and L T Vlasveld, and R Kröger, and R Dubbelman, and R G van Tol
Recombinant tissue plasminogen activator in the treatment of central venous catheter occlusion in children.
October 2001, The Journal of pediatrics,
S Rodenhuis, and L G van't Hek, and L T Vlasveld, and R Kröger, and R Dubbelman, and R G van Tol
Recombinant tissue plasminogen activator treatment of pulmonary embolism also improves deep venous thrombosis.
October 2018, Journal of investigative medicine : the official publication of the American Federation for Clinical Research,
S Rodenhuis, and L G van't Hek, and L T Vlasveld, and R Kröger, and R Dubbelman, and R G van Tol
Need for tissue plasminogen activator for central venous catheter dysfunction is significantly associated with thrombosis in pediatric cancer patients.
June 2018, Pediatric blood & cancer,
S Rodenhuis, and L G van't Hek, and L T Vlasveld, and R Kröger, and R Dubbelman, and R G van Tol
Late results of catheter-directed recombinant tissue plasminogen activator fibrinolytic therapy of iliofemoral deep venous thrombosis.
February 2007, Clinics (Sao Paulo, Brazil),
S Rodenhuis, and L G van't Hek, and L T Vlasveld, and R Kröger, and R Dubbelman, and R G van Tol
Recombinant tissue plasminogen activator for central venous access device occlusion.
July 2000, Journal of pediatric oncology nursing : official journal of the Association of Pediatric Oncology Nurses,
S Rodenhuis, and L G van't Hek, and L T Vlasveld, and R Kröger, and R Dubbelman, and R G van Tol
Demonstration of significant resolution of cerebral sino-venous thrombosis associated with intravenous recombinant tissue plasminogen activator.
October 2007, Journal of neuroimaging : official journal of the American Society of Neuroimaging,
S Rodenhuis, and L G van't Hek, and L T Vlasveld, and R Kröger, and R Dubbelman, and R G van Tol
Successful treatment of a catheter-related right atrial thrombosis with recombinant tissue plasminogen activator and heparin.
April 2002, Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer,
S Rodenhuis, and L G van't Hek, and L T Vlasveld, and R Kröger, and R Dubbelman, and R G van Tol
Treatment of portal venous thrombosis with selective superior mesenteric artery infusion of recombinant tissue plasminogen activator.
December 2003, Journal of vascular surgery,
S Rodenhuis, and L G van't Hek, and L T Vlasveld, and R Kröger, and R Dubbelman, and R G van Tol
Central Venous Catheter-directed Tissue Plasminogen Activator in Massive Pulmonary Embolism.
February 2018, Clinical practice and cases in emergency medicine,
S Rodenhuis, and L G van't Hek, and L T Vlasveld, and R Kröger, and R Dubbelman, and R G van Tol
Thrombolysis with recombinant tissue-type plasminogen activator in renal venous thrombosis in infancy.
October 1992, Lancet (London, England),
Copied contents to your clipboard!